Related Experiment Video
Updated: May 5, 2026

In vivo Imaging of Transgenic Leishmania Parasites in a Live Host
Published on: July 27, 2010
Lipid-Based Nanocarriers for Topical Therapy of Cutaneous Leishmaniasis: An Insight into the Mechanism of Action
Amina Riaz1,2, Muhammad Farhan Ali Khan3, Aamir Jalil4
1Department of Pharmacy, The Women University Multan, Multan 6000, Pakistan.
Abstract:
Cutaneous leishmaniasis (CL) is a parasitic infection caused by Leishmania species, affecting millions worldwide. The current treatment options for CL have several limitations, including low efficacy, inability to reach the target site, potential toxicity, and longer treatment duration, leading to poor patient compliance. Therefore, there is an urgent need for alternative treatments, especially topical ones, that are more effective, safe, and patient-friendly. Although numerous reviews have described the advantages of a wide range of nanoparticles in the treatment of CL, this review narrows its focus to the utilization of novel lipid-based nanocarriers for the topical treatment of CL, offering an in-depth analysis of the topical potential and mechanism of skin permeation of these lipidic nanocarriers. Lipid-based nanostructures such as liposomes, solid lipid nanoparticles, and nanostructured lipid carriers have been extensively studied for CL treatment, either alone or in combination with other drugs or therapies. These carriers can improve the bioavailability, stability, and efficacy of the drug, target the infected site, and reduce adverse effects on healthy tissues. Moreover, these can be easily formulated into different dosage forms, such as creams, gels, or ointments, for convenient topical application. Despite the many benefits of lipid-based carriers, there are still some challenges that need to be addressed, such as optimizing the formulation parameters, ensuring the reproducibility and scalability of the process, and evaluating the long-term safety and efficacy in clinical trials. This study aims to provide a comprehensive overview of the current state-of-the-art lipid-based nanocarriers for topical treatment of CL, covering the recent advances, limitations, clinical evidence, and prospects of this promising approach. In addition, the skin and macrophage targeting potential of various lipid-based nanocarriers is also discussed, which is especially helpful in treating the lesions of CL.
Insights
Novel lipid-based nanocarriers offer a promising topical treatment for cutaneous leishmaniasis (CL), overcoming limitations of current therapies. These advanced formulations enhance drug delivery and efficacy for this widespread parasitic skin infection.
Area of Science:
- Pharmacology and Drug Delivery
- Dermatology
- Parasitology
Background:
- Cutaneous leishmaniasis (CL) is a significant global health concern caused by Leishmania parasites.
- Existing CL treatments suffer from low efficacy, toxicity, and poor patient compliance.
- There is a critical need for improved, patient-friendly topical therapies for CL.
Purpose of the Study:
- To review the potential of lipid-based nanocarriers for topical treatment of CL.
- To analyze the skin permeation mechanisms and targeting capabilities of these nanocarriers.
- To provide a comprehensive overview of recent advances, challenges, and clinical prospects.
Main Methods:
- Literature review focusing on lipid-based nanocarriers (liposomes, SLNs, NLCs) for CL.
- Analysis of studies detailing formulation, drug delivery, and skin penetration.
- Evaluation of targeting potential to skin and macrophage cells.
Main Results:
- Lipid-based nanocarriers enhance bioavailability, stability, and efficacy of CL treatments.
- These nanocarriers demonstrate potential for targeted delivery to infected skin sites.
- Formulations like creams and gels offer convenient topical application.
Conclusions:
- Lipid-based nanocarriers represent a promising strategy for effective and safe topical CL treatment.
- Further research is needed to address formulation optimization, scalability, and long-term clinical efficacy.
- Targeting strategies are crucial for maximizing therapeutic outcomes in CL lesions.
More Related Videos
Related Concept Videos
Bioavailability Enhancement: Drug Permeability Enhancement
Modified-Release Drug Delivery Systems: Site-Targeted
Site-Targeted Drug Delivery Systems: Polymeric Carriers

